aTyr Pharma, Inc.
$ 0.75
0.78%
29 Dec - close price
- Market Cap 73,353,000 USD
- Current Price $ 0.75
- High / Low $ 0.75 / 0.71
- Stock P/E N/A
- Book Value 0.82
- EPS -0.83
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -1.03 %
- 52 Week High 7.29
- 52 Week Low 0.64
About
aTyr Pharma, Inc. is an innovative biotherapeutics company headquartered in San Diego, California, specializing in the development of advanced immunological therapies. Leveraging its proprietary signaling pathway technology, aTyr is focused on creating treatments for diverse inflammatory and neuromuscular diseases, aiming to fulfill critical unmet medical needs. The company is advancing a robust pipeline through meticulous research and strategic partnerships, positioning itself to make significant contributions to the biopharmaceutical landscape while delivering sustainable value to its investors. With a commitment to immune modulation, aTyr is poised for impactful growth in the evolving healthcare sector.
Analyst Target Price
$4.36
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-03-12 | 2024-11-07 | 2024-08-07 | 2024-05-02 | 2024-03-14 | 2023-11-09 | 2023-08-09 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -0.26 | -0.22 | -0.17 | -0.1809 | -0.2277 | -0.2256 | -0.23 | -0.25 | -0.2 | -0.22 | -0.29 | -0.26 |
| Estimated EPS | -0.17 | -0.1845 | -0.19 | -0.226 | -0.22 | -0.24 | -0.24 | -0.24 | -0.2 | -0.28 | -0.29 | -0.48 |
| Surprise | -0.09 | -0.0355 | 0.02 | 0.0451 | -0.0077 | 0.0144 | 0.01 | -0.01 | 0 | 0.06 | 0 | 0.22 |
| Surprise Percentage | -52.9412% | -19.2412% | 10.5263% | 19.9558% | -3.5% | 6% | 4.1667% | -4.1667% | 0% | 21.4286% | 0% | 45.8333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.183 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATYR
2025-12-15 20:09:14
Johnson Fistel, PLLP is investigating potential derivative claims against aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches related to disclosures about its Phase 3 EFZO-FIT clinical trial. The investigation focuses on whether the company and executives made false or misleading statements regarding the trial's design and likelihood of success, leading to a significant stock price drop. Shareholders who held shares before November 7, 2024, may have grounds for derivative claims.
2025-12-15 06:09:14
aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus "Hold" rating from eight brokerages, with an average one-year price target of $23.25. Despite recent insider buying by Director Paul Schimmel and increased holdings by institutional investors like Vanguard and UBS, the company missed its quarterly EPS and revenue estimates. Shares are currently trading around $0.78 with a market capitalization of approximately $76 million.
2025-12-12 21:08:31
The Gross Law Firm has announced a class action lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR), notifying investors who purchased shares between November 7, 2024, and September 12, 2025, of an upcoming deadline to register as lead plaintiff. The lawsuit alleges that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to help patients taper off steroid usage. This alleged deception led to a significant stock price decline after the EFZO-FIT study failed to meet its primary endpoint in September 2025.
2025-12-11 21:09:29
Levi & Korsinsky LLP has issued a lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ: ATYR) regarding a class action securities lawsuit. The lawsuit alleges that aTyr Pharma made false and misleading statements about the efficacy of its drug Efzofitimod, leading to an 83.2% stock price decline after the EFZO-FIT study failed to meet its primary endpoint. Investors who suffered losses between November 7, 2024, and September 12, 2025, are encouraged to learn about their rights to potentially recover losses, with a lead plaintiff deadline of December 8, 2025.
2025-12-11 09:56:00
Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) shareholders for alleged fiduciary breaches. The investigation focuses on disclosures related to the Phase 3 EFZO-FIT clinical trial, where executives allegedly made false or misleading statements about the trial's design, likelihood of success, and the drug's ability to eliminate steroid use. This probe follows a significant drop in the company's stock price after negative Phase 3 trial results.
2025-12-11 09:56:00
Johnson Fistel, PLLP is investigating potential derivative claims against aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches related to disclosures about its Phase 3 EFZO-FIT clinical trial. The investigation focuses on claims that aTyr and certain executives made misleading statements regarding the trial's design, its likelihood of meeting the primary endpoint, and the drug's ability to eliminate steroid use. This follows a significant drop in the company's stock price after negative Phase 3 trial results.
